Background & Aims: We aimed to evaluate the association of the patient-reported outcomes for rectal bleeding and stool frequency among patients with ulcerative colitis (UC) in endoscopic remission.
Methods: We performed a systematic review of studies reporting the association of patient-reported outcomes (the patient-reported components of the Mayo score: rectal bleeding and stool frequency) and endoscopic remission (Mayo endoscopic subscore of 0 or 1). We performed a meta-analysis of diagnostic accuracy using the hierarchical bivariate method.
Results: Our meta-analysis consisted of 5 studies comprising 2132 participants. A rectal bleeding subscore of 0 identified patients in endoscopic remission with a pooled sensitivity value of 81% (95% CI, 73%-86%), a specificity value of 68% (95% CI, 61%-75%), a positive likelihood ratio (LR) of 2.5 (95% CI, 2.2-3.0), and a negative LR of 0.28 (95% CI, 0.22-0.37). A stool frequency subscore of 0 identified patients in endoscopic remission with a pooled sensitivity value of 40% (95% CI, 25%-58%), a specificity value of 93% (95% CI, 86%-97%), a positive LR of 6.0 (95% CI, 3.7-9.7), and negative LR of 0.64 (95% CI, 0.50-0.82). A combined rectal bleeding and stool frequency subscore of 0 identified patients in endoscopic remission with a pooled sensitivity value of 36% (95% CI, 22%-54%), a specificity value of 96% (95% CI, 91%-98%), a positive LR or 8.4 (95% CI, 5.5-12.8), and a negative LR or 0.66 (95% CI, 0.53-0.84).
Conclusions: In a meta-analysis of 5 studies, we found that most patients with UC and normal rectal bleeding and stool frequency subscores have attained endoscopic remission. Many patients in endoscopic remission from UC have no rectal bleeding. Normal stool frequency associates with endoscopic remission, but many patients have abnormal stool frequencies despite endoscopic remission. These results should be carefully considered given the high heterogeneity and wide confidence intervals for some outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2018.06.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Dietary- and Disease-Related Influences on Flatulence and Fecal Odor Perception in Inflammatory Bowel Disease.
J Clin Med
December 2024
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
: Inflammatory bowel disease (IBD) affects gastrointestinal function and may alter fecal and flatulence odor (intestinal odor) due to changes in inflammation, the gut microbiome, and metabolism. Investigating the relationship between dietary habits and intestinal odor in IBD is critical given the relationship between diet, gut health, and microbiome diversity. : We performed a cohort analysis of a monocentric, cross-sectional study at a tertiary referral center and compared the perception of fecal and flatulence odor in 233 IBD patients (n = 117 women) with that of 96 healthy controls (HCs) (n = 67 women).
View Article and Find Full Text PDFFood Protein-Induced Allergic Proctocolitis: Real-World Experience from an Italian Cohort.
Nutrients
December 2024
Allergy Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
: Food protein-induced allergic proctocolitis (FPIAP) is a non-IgE-mediated food allergy, usually presenting as bloody stools in breastfed, well-appearing, and regularly growing infants. The aim of our study was to describe the clinical features of Italian infants affected by FPIAP and their management and natural history in a real-life setting. : A retrospective, observational study was performed at two tertiary pediatric hospitals (Florence and Trieste), including FPIAP-diagnosed infants between 2012 and 2022.
View Article and Find Full Text PDFWithdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
Gut
December 2024
Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain
Background And Objectives: Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it.
Secondary Objectives: to evaluate the effect of anti-TNF withdrawal on relapse-free time, endoscopic and radiological activity, safety, quality of life and work productivity; and to identify predictive factors for relapse.
Design: Prospective, quadruple-blind, multicentre, randomised, controlled trial.
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Lancet Gastroenterol Hepatol
January 2025
Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Background: Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis. We aimed to assess the safety and efficacy of tamuzimod in patients with moderately-to-severely active ulcerative colitis.
Methods: This double-blind, randomised, placebo-controlled, phase 2 induction trial was conducted at 122 centres across 15 countries in Asia, Europe, and North America.
Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.
Clin Transl Gastroenterol
January 2025
Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing, Germany.
Introduction: Vidofludimus calcium (VidoCa) is a dihydroorotate dehydrogenase (DHODH) inhibitor that demonstrated efficacy in immune-related diseases. This study assessed the safety and efficacy of VidoCa in patients with active ulcerative colitis (UC).
Methods: This placebo-controlled, phase 2 trial randomized adults with moderate-severe UC to receive once-daily VidoCa (10, 30, or 45 mg) or placebo for 10 weeks (induction); patients with symptomatic remission were re-randomized to VidoCa 10, 30 mg, or placebo once-daily for an additional 40 weeks (maintenance).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!